Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets with therapeutic potential.
暂无分享,去创建一个
M. Vignuzzi | C. Craik | P. Eyers | F. Agou | Y. Gambin | E. Sierecki | Philip J. Brownridge | C. Eyers | J. Chiaravalli | E. Emmott | Arturas Grauslys | Leonard A. Daly | Stacy Gellenoncourt | Dominic P. Bryne | Bjoern Meyer | Marius Walter | Lisa A. Chakrabarti | Andrew R. Jones | Eric Verdin | Andrew R Jones
[1] A. Telenti,et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 , 2021, bioRxiv.
[2] A. Tholey,et al. N‐Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS‐CoV‐2 Main Protease , 2020, Proteomics.
[3] C. Robinson,et al. Proteoforms of the SARS-CoV-2 nucleocapsid protein are primed to proliferate the virus and attenuate the antibody response , 2020 .
[4] Yong-tang Zheng,et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates , 2020, Nature Communications.
[5] S. Chanda,et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells , 2020, Cell Reports.
[6] N. Heaton,et al. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro , 2020, bioRxiv.
[7] C. Rice,et al. Defining the proteolytic landscape during enterovirus infection , 2020, PLoS pathogens.
[8] Haibo Liu,et al. dagLogo: An R/Bioconductor package for identifying and visualizing differential amino acid group usage in proteomics data , 2020, bioRxiv.
[9] Georgios A. Pavlopoulos,et al. Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms , 2020, bioRxiv.
[10] S. Munro,et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion , 2020, bioRxiv.
[11] D. Matthews,et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein , 2020, Genome Medicine.
[12] H. Mouquet,et al. Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.
[13] J. Skehel,et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects , 2020, Nature Structural & Molecular Biology.
[14] Jeremy L. Praissman,et al. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor , 2020, bioRxiv.
[15] Andrew R. Leach,et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.
[16] S. Brohawn,et al. Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs , 2020, bioRxiv.
[17] L. Pirofski,et al. Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis , 2020, bioRxiv.
[18] Dominic J. B. Hunter,et al. SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts , 2020, bioRxiv.
[19] C. Mills,et al. The COVID-19 MS Coalition—accelerating diagnostics, prognostics, and treatment , 2020, The Lancet.
[20] S. Ciesek,et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.
[21] S. Ciesek,et al. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication , 2020, bioRxiv.
[22] M. Schwartz,et al. The coding capacity of SARS-CoV-2 , 2020, Nature.
[23] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[24] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[25] Zongyang Lv,et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design , 2020, bioRxiv.
[26] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[27] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[28] Devin K. Schweppe,et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples , 2020, Nature Methods.
[29] R. Hilgenfeld,et al. Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging , 2020, bioRxiv.
[30] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[31] Young-Jun Park,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[32] Malik Peiris,et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.
[33] P. Horby,et al. A novel coronavirus outbreak of global health concern , 2020, The Lancet.
[34] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[35] Pitter F. Huesgen,et al. Sensitive Determination of Proteolytic Proteoforms in Limited Microscale Proteome Samples* , 2019, Molecular & Cellular Proteomics.
[36] Konstantinos D. Tsirigos,et al. SignalP 5.0 improves signal peptide predictions using deep neural networks , 2019, Nature Biotechnology.
[37] Martin Eisenacher,et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..
[38] P. Sanseau,et al. Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.
[39] Krishna Shankara Narayanan,et al. Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway , 2018, Proceedings of the National Academy of Sciences.
[40] Christopher S. Hughes,et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments , 2018, Nature Protocols.
[41] Akshay Bhumkar,et al. Unexpected instabilities explain batch‐to‐batch variability in cell‐free protein expression systems , 2018, Biotechnology and bioengineering.
[42] Colin W. Combe,et al. xiSPEC: web-based visualization, analysis and sharing of proteomics data , 2018, Nucleic Acids Res..
[43] S. Knapp. New opportunities for kinase drug repurposing and target discovery , 2018, British Journal of Cancer.
[44] Honglin Luo,et al. N-Terminomics TAILS Identifies Host Cell Substrates of Poliovirus and Coxsackievirus B3 3C Proteinases That Modulate Virus Infection , 2018, Journal of Virology.
[45] Conrad C. Huang,et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.
[46] Edoardo M. Airoldi,et al. Quantifying Homologous Proteins and Proteoforms* , 2017, Molecular & Cellular Proteomics.
[47] Ying Zhu,et al. Inducible TAP1 Negatively Regulates the Antiviral Innate Immune Response by Targeting the TAK1 Complex , 2017, The Journal of Immunology.
[48] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[49] Keely L. Szilágyi,et al. Epigenetic contribution of the myosin light chain kinase gene to the risk for acute respiratory distress syndrome , 2017, Translational research : the journal of laboratory and clinical medicine.
[50] Jüergen Cox,et al. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.
[51] R. Lloyd,et al. Norovirus-Mediated Modification of the Translational Landscape via Virus and Host-Induced Cleavage of Translation Initiation Factors , 2016, Molecular & Cellular Proteomics.
[52] A. Heck,et al. Six alternative proteases for mass spectrometry–based proteomics beyond trypsin , 2016, Nature Protocols.
[53] Valeria Nofrini,et al. Nucleoporin genes in human diseases , 2016, European Journal of Human Genetics.
[54] E. Emmott,et al. A Cell-based Fluorescence Resonance Energy Transfer (FRET) Sensor Reveals Inter- and Intragenogroup Variations in Norovirus Protease Activity and Polyprotein Cleavage , 2015, The Journal of Biological Chemistry.
[55] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[56] Jeff Barcus,et al. Identification of putative interactions between swine and human influenza A virus nucleoprotein and human host proteins , 2014, Virology Journal.
[57] Sharon Yang,et al. Proteome TopFIND 3.0 with TopFINDer and PathFINDer: database and analysis tools for the association of protein termini to pre- and post-translational events , 2014, Nucleic Acids Res..
[58] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[59] O. Schilling,et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.
[60] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[61] J. Coon,et al. Value of using multiple proteases for large-scale mass spectrometry-based proteomics. , 2010, Journal of proteome research.
[62] L. Foster,et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products , 2010, Nature Biotechnology.
[63] Xuguang Li,et al. SARS coronavirus: Unusual lability of the nucleocapsid protein , 2008, Biochemical and Biophysical Research Communications.
[64] H. Schätzl,et al. Cell Type-Specific Cleavage of Nucleocapsid Protein by Effector Caspases during SARS Coronavirus Infection , 2007, Journal of Molecular Biology.
[65] R. Beynon,et al. Positional proteomics: preparation of amino-terminal peptides as a strategy for proteome simplification and characterization , 2006, Nature Protocols.
[66] Rahul S Rajan,et al. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. , 2006, Analytical chemistry.
[67] J. Mesirov,et al. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .
[68] Andrew Pekosz,et al. Structure and Intracellular Targeting of the SARS-Coronavirus Orf7a Accessory Protein , 2005, Structure.
[69] W. Hong,et al. Characterization of a Unique Group-Specific Protein (U122) of the Severe Acute Respiratory Syndrome Coronavirus , 2004, Journal of Virology.
[70] K. Gevaert,et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides , 2003, Nature Biotechnology.
[71] John D. Storey. A direct approach to false discovery rates , 2002 .
[72] S. Prusiner,et al. Tandem mass spectrometry of peptides with N-terminal glutamine studies on a prion protein peptide , 1990 .
[73] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[74] A. Tholey,et al. N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease , 2020 .
[75] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[76] Cedric E. Ginestet. ggplot2: Elegant Graphics for Data Analysis , 2011 .